A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

This study is evaluating the long-term safety and effectiveness of a subcutaneous (under-the-skin) injectable form of vedolizumab — a medication that treats inflammatory bowel disease — in adults with moderate to severe ulcerative colitis or Crohn's disease in South Korea. **You may be eligible if:** - You have moderately to severely active ulcerative colitis or Crohn's disease - Your disease has not responded adequately to, or you could not tolerate, conventional therapy or anti-TNF medications - You have already shown benefit from at least 2 intravenous infusions of vedolizumab **You may NOT be eligible if:** - You have had a severe allergic reaction to vedolizumab (breathing difficulty, hives, rapid heartbeat) - You have an active serious infection such as tuberculosis, CMV, sepsis, or rare brain infection (PML) - Vedolizumab is contraindicated for you per the drug label Talk to your doctor to see if this trial is right for you.